Its in-house pipeline is headed by MORF-057, an orally-available alpha 4 beta 7 integrin inhibitor that is currently in phase 2 testing as a treatment for inflammatory bowel disease, specifically ...

The new formulation of the alpha-4 beta-7 integrin antagonist is intended for use after the current intravenous formulation of Entyvio (vedolizumab) is deployed as an induction therapy for the ...